Search

Hao Liu

EDUCATION:

Peking University, Beijing, China

B.S. in Mathematics

1995

University of California, Berkeley

M.A.  in Biostatistics

1998

University of Washington, Seattle

Ph.D. in Biostatistics

2004

 

ACADEMIC APPOINTMENTS:

2017 – current Professor, Department of Biostatistics, Indiana University School of Medicine, Indianapolis, IN
2017 – current Director, Biostatistics and Data Management Core, IU Simon Cancer Center
Indiana University School of Medicine, Indianapolis, IN
2011 – 2017   Associate Professor, Division of Biostatistics, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX
2017 Co-Director of Biostatistics, Biostatistics and Informatics Shared Resource, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX
2006 – 2011   Assistant Professor, Division of Biostatistics, Dan L. Duncan Comprehensive Cancer Center
Baylor College of Medicine, Houston, TX
2004 – 2006

Assistant Professor, Division of Biostatistics, Department of Public Health Sciences
University of California, Davis

 

Selected Awards and National Services:

2005

University of California Davis Academic Federation Innovative Developmental Award

2007

NIH Study Section, Early Clinical Trials of New Anti-Cancer Agent with Phase-1 Emphasis

2009

NIH Challenge Grant Cancer Biomarker Section

2012

NIH Clinical Oncology Study Section

2012-2014

President Elect, President, Past President, Houston Area Chapter, American Statistical Association

2014

DoD CDMRP Peer Review Panel, Prostate Cancer Research Program

2015

NIH Infectious Disease, Reproductive Health, and Asthma/Pulmonary Conditions Study Section

2016

DoD CDMRP Peer Review Panel, Ovarian Cancer Research Program

 

 

Editorial Boards:

2014-current, Journal of the National Cancer Institute

2013-current, Journal of Clinical Oncology


Research Interests:

Fascinated by science and stochastic modelling, my personal passion is the use and development of elegant statistical methods for solving quantitative problems arising from the collaborations with clinical investigators and basic scientists, whether it is the innovative clinical trial designs or the analysis of messy big data.
 

The current research interests are 

  • Survival analysis with complicated designs
  • Innovative designs for genomic-guided oncology trials
  • Statistical learning for cancer genomic data 
  • Multivariate recurrent events data

We are actively looking for motivated PhD students and post-docs to work on these exciting areas!

 

Selected Publications (from 106 peer reviewed publications)

My major contribution is the development of statistical methodology for the analysis of biomedical data including preclinical data, clinical trials as well as population epidemiology data. For example, we have developed novel statistical methods for the analysis and design of cross-sectional prevalent cohort studies, which is directly relevant to the proposed project for population screening.

  • Liu H, Lin X, Huang X. An oncology clinical trial design with randomization adaptive to both short- and long-term responses. Statistical Methods in Medical Research. 2017 Jan 1:962280217744816. doi: 10.1177/0962280217744816. [Epub ahead of print] PMID: 29233085
  • Liu H. and Qin J. Semiparametric probit models with univariate and bivariate current status data. Biometrics. 2017 Apr 24. doi: 10.1111/biom.12709. [Epub ahead of print] PMID: 28437561
  • Liu H, Shen Y, Ning J, Qin J. Sample size calculations for prevalent cohort designs. Statistical Methods in Medical Research. 2017 Feb;26(1):280-291. PubMed PMID: 25091809; PubMed Central PMCID: PMC4317376.
  • Liu H, Ning J, Qin J and Shen Y. Semiparametric Maximum Likelihood Inference for Truncated or Biased-Sampling Data. Statistica Sinica, 26 (2016), 1087-1115
  • Shu Y., Feng Q., Kao E., Liu H., Levy Driven Non-Gaussian Ornstein-Uhlenbeck Processes for Degradation-Based Reliability Analysis. IIE Transactions, 48(11), 993-1003, 2016.
  • Qin J., Ning J., Liu H. and Shen, Y. Maximum likelihood estimations and EM algorithms with length-biased data. Journal of the American Statistical Association – Theory and Methods. 106, no. 496, 1434-1449, 2011
  • Liu H, Shen Y. A Semiparametric Regression Cure Model for Interval-Censored Data. Journal of the American Statistical Association – Theory and Methods. 104, no. 487, 1168-1178, 2009. PubMed PMID: 20354594; PubMed Central PMCID: PMC2846840.
  • Liu H., Beckett, L. A. and DeNardo, G. L. On the Analysis of Count Data of Birth-and-Death Process Type with Application to Molecular Targeted Cancer Therapy. Statistics in Medicine. 26:1114-1135, 2007
  • Wellner, J. A., Zhang, Y. and Liu H. A semiparametric regression model for panel count data: when do pseudo-likelihood estimators become badly inefficient? In Proceedings of the Second Seattle Symposium in Biostatistics: Analysis of Correlated Data. Lin, D.Y., and Heagerty, P.J. (Eds.). 2005. Springer-Verlag, New York.
  • Yasui, Y., Liu H., Benach, J. and Winget, M. An empirical evaluation of various priors in empirical Bayes estimation of small-area disease risks. Statistics in Medicine, 2000 19, 2409-2420. [PIMD 10960862]

Additionally, I have the experience and skills in the statistical analysis with predictive and prognostic models as well as learning from large genomic data.

  • Chang E, Liu H, West JA, Zhou X, Dakhova O, Wheeler DA, Heslop HE, Brenner MK, Dotti G. Clonal Dynamics in vivo of Virus Integration Sites of T cells expressing a safety switch. Mol Ther. 2016 Apr;24(4):736-45.
  • Ayala GE, Muezzinoglu B, Hammerich KH, Frolov A, Liu H, Scardino PT, Li R, Sayeeduddin M, Ittmann MM, Kadmon D, Miles BJ, Wheeler TM, Rowley DR. Determining prostate cancer-specific death through quantification of stromogenic carcinoma area in prostatectomy specimens. Am J Pathol. 2011 Jan;178(1):79-87. PubMed PMID: 21224046; PubMed Central PMCID: PMC3069909.
  • Egler RA, Li Y, Dang TA, Peters TL, Leung E, Huang S, Russell HV, Liu H, Man TK. An integrated proteomic approach to identifying circulating biomarkers in high-risk neuroblastoma and their potential in relapse monitoring. Proteomics Clin Appl. 2011 Oct;5(9-10):532-41. PubMed PMID: 21833997; PubMed Central PMCID: PMC3685293.
  • Lerner SP, Liu H, Wu MF, Thomas YK, Witjes JA. Fluorescence and white light cystoscopy for detection of carcinoma in situ of the urinary bladder. Urol Oncol. 2012 May-Jun;30(3):285-9. PubMed PMID: 21396840.
  • Liebig C, Ayala G, Wilks J, Verstovsek G, Liu H, Agarwal N, Berger DH, Albo D. Perineural Invasion Is an Independent Predictor of Outcome in Colorectal Cancer. Journal of Clinical Oncology. 2009 Nov 1;27(31):5131-7. [Epub 2009 Sep 8. PMID: 19738119]
  • Nguyen, D.V., Liu H. and Senturk, D. A general FDR-based computational framework for sample size planning in microarray studies. In Advanced Computational Methods for Biocomputing and Bioimaging, Pham, T., Yan, H., and Crane, D. (eds). 2007.  Nova Science Publishers, New York, p. 55-69.
  • Ye J, Liu H, Kirmiz C, Lebrilla CB, Rocke DM. On the analysis of glycomics mass spectrometry data via the regularized area under the ROC curve. BMC Bioinformatics. 2007 Dec 12;8:477. PubMed PMID: 18076765; PubMed Central PMCID: PMC2211327.

In the past decades, I have been working closely with the clinicians and basic scientists in cancer research. For example, we have made several new modifications to the phase I trial designs, which have been used by the investigators conducting the clinical trials for novel T-cell based immunotherapies.

  • Bollard CM, Tripic T, Cruz CR, Dotti G, Gottschalk S, Torrano V, Dakhova O, Carrum G, Ramos CA, Liu H, Wu MF, Marcogliese AN, Barese C, Zu Y, Lee DY, O'Connor O, Gee AP, Brenner MK, Heslop HE, Rooney CM. Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma. J Clin Oncol. 2018 Jan 9:JCO2017743179. doi: 10.1200/JCO.2017.74.3179. [Epub ahead of print] PMID: 29315015
  • Fuery A, Leen AM, Peng R, Wong MC, Liu H, Ling PD. Asian elephant T cell responses to Elephant Endotheliotropic Herpesvirus (EEHV). J Virol. 2017 Dec 20. pii: JVI.01951-17. doi: 10.1128/JVI.01951-17. [Epub ahead of print] PMID: 29263271 Free Article
  • Ahmed N, Brawley V, Hegde M, Bielamowicz K, Kalra M, Landi D, Robertson C, Gray TL, Diouf O, Wakefield A, Ghazi A, Gerken C, Yi Z, Ashoori A, Wu MF, Liu H, Rooney C, Dotti G, Gee A, Su J, Kew Y, Baskin D, Zhang YJ, New P, Grilley B, Stojakovic M, Hicks J, Powell SZ, Brenner MK, Heslop HE, Grossman R, Wels WS, Gottschalk S. HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial. JAMA Oncol. 2017 Aug 1;3(8):1094-1101. PubMed PMID: 28426845; PubMed Central PMCID: PMC5747970.
  • Di Stasi A, Tey SK, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C, Straathof K, Liu E, Durett AG, Grilley B, Liu H, Cruz CR, Savoldo B, Gee AP, Schindler J, Krance RA, Heslop HE, Spencer DM, Rooney CM, Brenner MK. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med. 2011 Nov 3;365(18):1673-83. PubMed PMID: 22047558; PubMed Central PMCID: PMC3236370.
  • Nishio N, Diaconu I, Liu H, Cerullo V, Caruana I, Hoyos V, Bouchier-Hayes L, Savoldo B, Dotti G. Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors. Cancer Res. 2014 Sep 15;74(18):5195-205. PubMed PMID: 25060519; PubMed Central PMCID: PMC4167556.
  • Ramos CA, Savoldo B, Torrano V, Ballard B, Zhang H, Dakhova O, Liu E, Carrum G, Kamble RT, Gee AP, Mei Z, Wu MF, Liu H, Grilley B, Rooney CM, Brenner MK, Heslop HE, Dotti G. Clinical responses with T lymphocytes targeting malignancy-associated κ light chains. J Clin Invest. 2016 Jul 1;126(7):2588-96. PubMed PMID: 27270177; PubMed Central PMCID: PMC4922690.

Department of Biostatistics | 410 W. Tenth St., Suite 3000 | Indianapolis, IN 46202 | Ph: (317) 274-2661 | Fax: (317) 274-2678